A detailed history of Geode Capital Management, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,571,081 shares of RARE stock, worth $70.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,571,081
Previous 1,505,458 4.36%
Holding current value
$70.3 Million
Previous $61.9 Million 41.05%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.21 - $59.36 $2.64 Million - $3.9 Million
65,623 Added 4.36%
1,571,081 $87.3 Million
Q2 2024

Aug 09, 2024

BUY
$37.42 - $51.61 $6.2 Million - $8.55 Million
165,632 Added 12.36%
1,505,458 $61.9 Million
Q1 2024

May 13, 2024

BUY
$43.02 - $53.69 $2.42 Million - $3.02 Million
56,204 Added 4.38%
1,339,826 $62.6 Million
Q4 2023

Feb 13, 2024

BUY
$31.73 - $49.19 $6.36 Million - $9.85 Million
200,335 Added 18.49%
1,283,622 $61.4 Million
Q3 2023

Nov 13, 2023

BUY
$34.92 - $46.66 $791,776 - $1.06 Million
22,674 Added 2.14%
1,083,287 $38.6 Million
Q2 2023

Aug 11, 2023

BUY
$37.35 - $52.15 $1.72 Million - $2.4 Million
45,973 Added 4.53%
1,060,613 $48.9 Million
Q1 2023

May 15, 2023

BUY
$36.99 - $48.71 $1.17 Million - $1.54 Million
31,610 Added 3.22%
1,014,640 $40.7 Million
Q4 2022

Feb 13, 2023

BUY
$33.72 - $46.33 $1.96 Million - $2.69 Million
58,153 Added 6.29%
983,030 $45.5 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $645,913 - $1.07 Million
16,164 Added 1.78%
924,877 $38.3 Million
Q2 2022

Aug 12, 2022

BUY
$45.8 - $85.4 $266,235 - $496,430
5,813 Added 0.64%
908,713 $54.2 Million
Q1 2022

May 13, 2022

BUY
$62.2 - $84.4 $1.61 Million - $2.19 Million
25,944 Added 2.96%
902,900 $65.6 Million
Q4 2021

Feb 11, 2022

BUY
$73.71 - $87.86 $2.28 Million - $2.71 Million
30,889 Added 3.65%
876,956 $73.7 Million
Q3 2021

Nov 12, 2021

BUY
$77.92 - $102.4 $2.41 Million - $3.16 Million
30,868 Added 3.79%
846,067 $76.3 Million
Q2 2021

Aug 13, 2021

SELL
$92.19 - $115.71 $24.1 Million - $30.2 Million
-261,334 Reduced 24.28%
815,199 $77.7 Million
Q1 2021

May 12, 2021

BUY
$106.9 - $167.73 $10.6 Million - $16.7 Million
99,514 Added 10.19%
1,076,533 $123 Million
Q4 2020

Feb 12, 2021

BUY
$84.4 - $177.39 $9.98 Million - $21 Million
118,222 Added 13.77%
977,019 $135 Million
Q3 2020

Nov 13, 2020

BUY
$72.98 - $90.0 $72,615 - $89,550
995 Added 0.12%
858,797 $70.6 Million
Q2 2020

Aug 13, 2020

BUY
$46.91 - $78.22 $1.92 Million - $3.19 Million
40,827 Added 5.0%
857,802 $67.1 Million
Q1 2020

May 14, 2020

BUY
$33.8 - $62.9 $2.44 Million - $4.54 Million
72,120 Added 9.68%
816,975 $36.3 Million
Q4 2019

Feb 13, 2020

BUY
$36.08 - $45.83 $475,390 - $603,856
13,176 Added 1.8%
744,855 $31.8 Million
Q3 2019

Nov 12, 2019

BUY
$42.5 - $63.11 $314,075 - $466,382
7,390 Added 1.02%
731,679 $31.3 Million
Q2 2019

Aug 14, 2019

BUY
$54.93 - $74.36 $2.91 Million - $3.94 Million
53,043 Added 7.9%
724,289 $46 Million
Q1 2019

May 14, 2019

BUY
$39.87 - $69.36 $4.11 Million - $7.15 Million
103,016 Added 18.13%
671,246 $46.6 Million
Q4 2018

Feb 13, 2019

BUY
$38.89 - $77.3 $2.45 Million - $4.88 Million
63,118 Added 12.5%
568,230 $24.7 Million
Q3 2018

Nov 13, 2018

BUY
$71.81 - $90.15 $1.84 Million - $2.31 Million
25,598 Added 5.34%
505,112 $38.6 Million
Q2 2018

Aug 14, 2018

BUY
$48.54 - $85.31 $2.16 Million - $3.79 Million
44,442 Added 10.21%
479,514 $36.9 Million
Q1 2018

May 15, 2018

BUY
$44.33 - $58.52 $3.19 Million - $4.21 Million
71,882 Added 19.79%
435,072 $22.2 Million
Q4 2017

Feb 13, 2018

SELL
$43.54 - $57.32 $18,243 - $24,017
-419 Reduced 0.12%
363,190 $16.8 Million
Q3 2017

Nov 14, 2017

BUY
$49.79 - $66.32 $765,272 - $1.02 Million
15,370 Added 4.41%
363,609 $19.4 Million
Q2 2017

Aug 14, 2017

BUY
N/A
348,239
348,239 $21.6 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.